Related Experiment Video

Updated: Jun 25, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in

Tamara Montes1, Agustín Tortajada, B Paul Morgan

  • 1Consejo Superior de Investigaciones Cientificas, Centro de Investigación Biomédica en Red de Enfermedades Raras and Fundación Renal Iñigo Alvarez de Toledo, Ramiro de Maeztu 9, 28040 Madrid, Spain.

Proceedings of the National Academy of Sciences of the United States of America
|March 4, 2009
PubMed

Insights

The factor B (fB) Gln (fB(32Q)) allele, protective against age-related macular degeneration, shows reduced complement system activation. This finding offers insights into predicting and treating complement-related disorders.

Area of Science:

  • Immunology
  • Genetics
  • Biochemistry

Background:

  • Complement gene mutations are linked to various disorders.
  • Factor B (fB) has three common alleles: Arg (fB(32R)), Gln (fB(32Q)), and Trp (fB(32W)).
  • The fB(32Q) allele is protective against age-related macular degeneration.

Purpose of the Study:

  • To investigate the functional differences between fB variants.
  • To understand the mechanism behind the protective effect of fB(32Q).

Main Methods:

  • Purification and functional testing of fB variants from plasma.
  • Hemolysis assays to measure complement activity.
  • Biacore analysis to determine binding affinities and kinetics.
  • Testing of recombinant fB variants.

Main Results:

  • The protective fB(32Q) variant exhibited decreased activity compared to fB(32R).
  • fB(32R) showed a 4-fold higher affinity for C3b, enhancing convertase formation.
  • fB(32W) displayed intermediate binding affinity.
  • The Ba domain of fB(32R) had a 3-fold higher affinity for C3b than fB(32Q).

Conclusions:

  • The protective effect of fB(32Q) is due to its reduced capacity to form convertase and amplify complement activation.
  • Understanding functional consequences of complement gene polymorphisms aids disease prediction and therapeutic targeting.

More Related Videos

Enrichment of Bruch's Membrane from Human Donor Eyes10:22

Enrichment of Bruch's Membrane from Human Donor Eyes

Published on: November 15, 2015

Efficient Dissection and Culture of Primary Mouse Retinal Pigment Epithelial Cells08:33

Efficient Dissection and Culture of Primary Mouse Retinal Pigment Epithelial Cells

Published on: February 10, 2021

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Genetic Lingo01:11

Genetic Lingo

Overview
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.